| Name | Title | Contact Details |
|---|
Village on Lee Retirement Center is a Lawton, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BluMetric is a new company built on a proud past. Its five originating operating companies, WESA, WESAtech, Envir-Eau, OEL-HydroSys, and Seprotech, are internationally known for cutting-edge work in the fields of water/wastewater treatment and professional environmental services. Our combined staff of approximately 170 scientists, engineers, industrial hygienists, environmental auditors, project managers, financial management specialists and support personnel are uniquely equipped to undertake environmental projects of any size, in any industry. Innovation, agility and client-responsive service are our hallmarks.
Metabolex, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Metabolex, Inc. is based in Hayward, CA. You can find more information on Metabolex, Inc. at www.metabolex.com
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China. Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.